New Web-Based Tool Monitors Emergence of SARS-CoV-2 Variants and Their Impact on COVID-19 Diagnostic Tests
By LabMedica International staff writers Posted on 14 Jun 2021 |
Illustration
A new open access tool provides virologists and COVID-19 test developers insight to the latest viral variants and primer designs used around the world.
New England Biolabs, Inc. (Ipswich, MA, USA) has launched a web-based tool for monitoring the emergence of SARS-CoV-2 variants and their potential impact on COVID-19 diagnostic tests. The Primer Monitor Tool, which is updated regularly, provides simple visualization of known variants identified in the SARS-CoV-2 genome and offers insight into where commonly used or user-defined primer set assessment may be worthwhile.
As the SARS-CoV-2 virus has continued to spread and mutate, concerns have been raised about the effectiveness of current diagnostic tests to detect new strains of the virus. The US Food and Drug Administration (FDA) has issued guidance advising COVID-19 diagnostic developers to evaluate the impact of emerging and future SARS-CoV-2 variants on current diagnostic tests by routinely monitoring sequence alignment of primer/probe sequences with open access SARS-CoV-2 genomes databases such as GISAID, a global science initiative and primary source that provides open-access to genomic data of influenza viruses and the novel coronavirus responsible for COVID-19.
"With the issuance of the FDA guidance, we saw a need for creating an online tool for diagnostic researchers and developers that visualizes all of the SARS-CoV-2 genomic data and variant strains uploaded to the GISAID database," said Steven Chiu, Product Marketing Manager, DNA Amplification, at NEB. "The tool is pre-loaded with commonly used primer sequences from SARS-CoV-2 qPCR and LAMP assays and ARTIC sequencing workflows (currently v3). Users can monitor those predefined primer sets as well as upload their own sequences of interest, with the option to subscribe and be alerted should variation cross a specified threshold in a geographic region of interest."
Related Links:
New England Biolabs, Inc.
New England Biolabs, Inc. (Ipswich, MA, USA) has launched a web-based tool for monitoring the emergence of SARS-CoV-2 variants and their potential impact on COVID-19 diagnostic tests. The Primer Monitor Tool, which is updated regularly, provides simple visualization of known variants identified in the SARS-CoV-2 genome and offers insight into where commonly used or user-defined primer set assessment may be worthwhile.
As the SARS-CoV-2 virus has continued to spread and mutate, concerns have been raised about the effectiveness of current diagnostic tests to detect new strains of the virus. The US Food and Drug Administration (FDA) has issued guidance advising COVID-19 diagnostic developers to evaluate the impact of emerging and future SARS-CoV-2 variants on current diagnostic tests by routinely monitoring sequence alignment of primer/probe sequences with open access SARS-CoV-2 genomes databases such as GISAID, a global science initiative and primary source that provides open-access to genomic data of influenza viruses and the novel coronavirus responsible for COVID-19.
"With the issuance of the FDA guidance, we saw a need for creating an online tool for diagnostic researchers and developers that visualizes all of the SARS-CoV-2 genomic data and variant strains uploaded to the GISAID database," said Steven Chiu, Product Marketing Manager, DNA Amplification, at NEB. "The tool is pre-loaded with commonly used primer sequences from SARS-CoV-2 qPCR and LAMP assays and ARTIC sequencing workflows (currently v3). Users can monitor those predefined primer sets as well as upload their own sequences of interest, with the option to subscribe and be alerted should variation cross a specified threshold in a geographic region of interest."
Related Links:
New England Biolabs, Inc.
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants